PRA Health Sciences nomme un haut responsable de la FDA pour diriger le nouveau Centre mondial d’excellence pour la stratégie d’essais cliniques décentralisés

NEXT STORY
Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PREV STORY
Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

LifeMD Q1 2021 Revenues on Track to Exceed $17 Million, up 295%, with Subscriptions Representing More than 80% of Total Revenue

author_avatar
NASDAQ Market News

Merus annonce ses résultats financiers pour le deuxième trimestre et fait le point sur ses activités

author_avatar
NASDAQ Market News

PolyPid Announces Positive FDA Type B Meeting Feedback for D-PLEX₁₀₀ Development Program

author_avatar
NASDAQ Market News